In patients with hemophilia A (n=19), treatment with EHL FVIII resulted in a 75.0% reduction in ABR score (median) from baseline (20) to 6 (5) months (p=3.81×10−6), 75.0% (5) at 12 months (p=3.81×10−6), and 75.0% (5) at 24 months (p=3.81×10−6) compared to the baseline (Figure 1). Here, F8 is linked to hemophilia A.